Further studies are needed to deepen our knowledge of TIGIT expression, both in the neoplastic microenvironment and in tumor cells, and its substantial correlation with the PD1/PD-L1 axis, particularly in the field of lung cancer, on which most immunotherapy trials are focused. This evidence concerns the gene TIGIT and neoplasm.